These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 183852)

  • 1. The application of a digital whole body scanner to the dosimetry of intralymphatic 32P/131I Lipiodol.
    O'Connell EA; Steere HA; Trott NG
    Br J Radiol; 1976 Sep; 49(585):779-87. PubMed ID: 183852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution pattern of radioactive labelled lipiodol-UF following intralymphatic application for therapy.
    Weissleder H; Pfannenstiel P; Peters PE
    Lymphology; 1976 Sep; 9(3):122-6. PubMed ID: 187879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient dosimetry for 131I-lipiodol therapy.
    Monsieurs MA; Bacher K; Brans B; Vral A; De Ridder L; Dierckx RA; Thierens HM
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):554-61. PubMed ID: 12690415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reliability of the diagnostic results obtained with confined quantities of the contrast medium in endolymphatic radionuclide therapy (ELRT) of the inferior limbs (author's transl)].
    Müller RP; Schnepper E; Peters PE; Fladerer W
    Strahlentherapie; 1980 Aug; 156(8):538-41. PubMed ID: 7414647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lymphographically detectable long-term changes caused by endolymphatic radionuclide therapy (ELRT) in the infradiaphragmatic lymph system].
    Müller RP; Peters PE
    Strahlentherapie; 1985 Apr; 161(4):239-43. PubMed ID: 2986321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
    De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
    J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Behavior of pulmonary radioactivity in patients exposed to endolymphatic radiotherapy with lipiodol F-I 131].
    Bagliani G; Buraggi GL; De Vecchi A; Fava G
    Tumori; 1967; 53(3):225-35. PubMed ID: 4293146
    [No Abstract]   [Full Text] [Related]  

  • 8. [Endolymphatic lipiodol-P32 therapy in melanoma of the limbs during clinical stage 1].
    Kokoschka E
    Med Welt; 1974 Jun; 25(23):1054-5. PubMed ID: 4369551
    [No Abstract]   [Full Text] [Related]  

  • 9. [Indication establishment and dosimetry in endolymphatic therapy with I-131 lipiodol].
    Winkel K; Becker J; Jahns E; Scheurlen H; Herzfeld U
    Strahlentherapie; 1967 Aug; 133(4):481-98. PubMed ID: 4298455
    [No Abstract]   [Full Text] [Related]  

  • 10. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma.
    Raoul JL; Guyader D; Bretagne JF; Heautot JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M
    Hepatology; 1997 Nov; 26(5):1156-61. PubMed ID: 9362356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric assessment of radiolabelled lipiodol as a potential therapeutic agent in colorectal liver metastases using combined CT and SPECT.
    Perring S; Hind R; Fleming J; Birch S; Batty V; Taylor I
    Nucl Med Commun; 1994 Jan; 15(1):34-8. PubMed ID: 8152691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
    Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary oil deposition in patients subjected to lymphography: Detection by thoracic photoscan and sputum examination.
    Richardson P; Crosby EH; Bean HA; Dexter D
    Can Med Assoc J; 1966 May; 94(21):1086-91. PubMed ID: 4286715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body distribution of intralymphatically injected radioactive colloid and oil.
    Erjavec M; Hacek S; Havlicek M; Klanjscek G
    Radiobiol Radiother (Berl); 1969; 10(4):571-8. PubMed ID: 4312058
    [No Abstract]   [Full Text] [Related]  

  • 15. [Dosimetry in rabbit lymph nodes following endolymphatic therapy using radionuclides].
    Magnus L
    Strahlentherapie; 1973 Nov; 146(5):566-75. PubMed ID: 4362314
    [No Abstract]   [Full Text] [Related]  

  • 16. [Radiation-dosimetry studies after endolymphatic radionuclide therapy].
    Pfannenstiel P
    Med Welt; 1974 Jun; 25(23):1038-42. PubMed ID: 4369658
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical results of endolymphatic radionuclide therapy in the treatment of malignant melanoma].
    Makoski HB; Magnus L; Heissen E; Kolpatzik H; Drepper H
    Strahlentherapie; 1974 Jul; 148(1):1-15. PubMed ID: 4612879
    [No Abstract]   [Full Text] [Related]  

  • 18. The absorbed dose to bone marrow in the treatment of polycythaemia by 32P.
    Spiers FW; Beddoe AH; King SD
    Br J Radiol; 1976 Feb; 49(578):133-40. PubMed ID: 938829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution of intravenously injected [131I]Lipiodol in rats.
    Seto H; Tsuji S; Watanabe N; Futatsuya R; Nomura K; Maeda M; Kakishital M
    Radiat Med; 1992; 10(5):196-8. PubMed ID: 1332132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.